Niklas Klümper

University Hospital Bonn
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Objectives: The aim of this study was to assess the association of diabetes mellitus and its medications with overall response (ORR) and mortality or cancer-specific survival (CSS) in patients with metastatic urothelial cancer receiving enfortumab vedotin monotherapy. Methods: This multicentre retrospective cohort study was designed according to the guidelines for the synthesis of qualitative research (ENTREQ). Eligible patients were adults (≥18) years treated with enfortumab vedotin monotherapy for metastatic urothelial cancer between June 2024 and January 2025. A total of 125 patients were reported across 11 centres. Results: The cohort included 93 males (74.4%) and 32 females (25.6%), with a mean age of 68.3 years (SD 9.3). The primary tumour site was the bladder in 109 (87.2%) cases and the upper tract (UTUC) in 16 (12.8%) cases. Interestingly, medication with metformin was significantly associated with cancer-specific mortality (37.9% versus 77.8%; p = 0.019), while patients with insulin-dependent diabetes mellitus had a significantly better CSS (Log Rank = 0.004). Upon comparing only patients who already had diabetes mellitus and then received anti-diabetic medication, there was a significant association between patients with diabetes mellitus receiving metformin and a worse 3-month ORR (80.0% versus 55.6%; p = 0.039). Regarding the subpopulation of UTUC, cancer-specific mortality was significantly associated with metformin medication (p = 0.033). Conclusions: Despite recent reports that metformin has protective effects in urothelial cancer, our findings suggest that metformin use may be linked to worse responses and survival outcomes in patients treated with enfortumab vedotin monotherapy. Further research, particularly translational research into the underlying diabetic and pharmacologic pathways, is warranted.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Supplementary Figure 1. Expression of membranous NECTIN-4 in UC histology subtypes in PRIM (A) and MET (B). (C) depicts differential NECTIN-4 expression during metastatic spread. Intergroup comparison was calculated by non-parametric Kruskal-Wallis test.

Year:

2025

Supplementary Table 1. Clinico-pathological characteristics of the UC progression PRIM-MET study cohort. BRA=brain metastasis; HEP=hepatic metastasis; LYM=non-locoregionary lymph node metastasis; OSS=bone metastasis; OTH= metastasis at other locations including soft tissue; PER=peritoneal metastasis; PUL=pulmonary metastasis.

Year:

2025

TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).

Year:

2025

Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray ( n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro . IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC 50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.

Year:

2025

Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray (n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro. IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.

Year:

2025

Clear cell renal cell carcinoma (ccRCC) is characterized by marked histological heterogeneity, encompassing its vasculature. Here, we introduce PropSegNet, a learning-based algorithm that segments and classifies three distinct vascular patterns in CD31-stained tissue sections. Integrating transcriptomic features, our work identifies a trajectory from high- to low-branching vessel architecture that co-evolves with the loss of proximal tubular cell traits in tumor cells. Furthermore, low-branching vessels form niches enriched with T cells and antigen-presenting cells. Mechanistically, air-liquid-interface cultures of patient-derived tumor fragments confirm that low-branching vessel features associate with T cell infiltration resulting in reduced viability under IL-2 rich conditions. Post-hoc transcriptomic analyses from two phase III clinical trials demonstrate that patients with tumors exhibiting an inflamed, low-branching vascular phenotype benefit most from the addition of immune checkpoint inhibition to anti-angiogenic treatment. These findings provide a rationale for prospective evaluation of vascular patterns and vessel-immune cell niches as potential biomarkers in ccRCC.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (23)

Michael Hölzel

Director/MD, Professor

University Hospital Bonn

GERMANY
View details

SARA DE MARTIN

University of Padova

ITALY
View details

Matthias Geyer

Director

University of Bonn

GERMANY
View details

DANIELA GABBIA

University of Padua

ITALY
View details

Dagmar Wachten

Prof. Dr

University of Bonn

GERMANY
View details

Glen Kristiansen

-

GERMANY
View details

Johannes Brägelmann

Professor

University Hospital Bonn

GERMANY
View details

Tobias Bald

Group Leader

University Hospital Bonn

GERMANY
View details

Philipp Erben

Laboratory Head

University Medical Centre Mannheim

GERMANY
View details

Oliver Hahn

Attending urologist

University Hospital Würzburg

GERMANY
View details

Annemarie Uhlig

Staff

University Medical Center Göttingen

GERMANY
View details

Jörg Ellinger

University Hospital Bonn

GERMANY
View details

Fabian Hörst

University Hospital Essen

GERMANY
View details

Kristina Schwamborn

Technical University of Munich

GERMANY
View details

Jens Kleesiek

-

GERMANY
View details

Maria A. Gonzalez‐Carmona

-

GERMANY
View details

Philipp Krausewitz

-

GERMANY
View details

Wilko Weichert

University Hospital Heidelberg

GERMANY
View details

Christoph Kuppe

Professor

RWTH Aachen University

GERMANY
View details

Laila Schneidewind

University of Bern

SWITZERLAND
View details

Steffen Rausch

University Hospital Tübingen

GERMANY
View details

Viktor Grünwald

Director

University Hospital Essen

GERMANY
View details

Alexander Effland

University of Bonn

GERMANY
View details